Does CABAZITAXEL Cause Myelosuppression? 14 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Myelosuppression have been filed in association with CABAZITAXEL (Jevtana). This represents 0.6% of all adverse event reports for CABAZITAXEL.
14
Reports of Myelosuppression with CABAZITAXEL
0.6%
of all CABAZITAXEL reports
0
Deaths
3
Hospitalizations
How Dangerous Is Myelosuppression From CABAZITAXEL?
Of the 14 reports, 3 (21.4%) required hospitalization, and 2 (14.3%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CABAZITAXEL. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does CABAZITAXEL Cause?
Febrile neutropenia (197)
Malignant neoplasm progression (172)
Fatigue (160)
Prostatic specific antigen increased (148)
Pyrexia (145)
Disease progression (143)
Diarrhoea (142)
Anaemia (127)
Neutropenia (126)
Drug ineffective (125)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which CABAZITAXEL Alternatives Have Lower Myelosuppression Risk?
CABAZITAXEL vs CABERGOLINE
CABAZITAXEL vs CABOTEGRAVIR
CABAZITAXEL vs CABOTEGRAVIR\RILPIVIRINE
CABAZITAXEL vs CABOZANTINIB
CABAZITAXEL vs CABOZANTINIB S-MALATE